ImmunoGen’s IMGN529 For B-Cell Malignancies Demonstrates Synergistic Activity With Rituximab In Preclinical Models Of Non-Hodgkin Lymphoma

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first presentation of findings with the Company’s CD37-targeting ADC, IMGN529, in combination with the CD20-targeting antibody, rituximab (Rituxan®), in preclinical assessments. These data are being presented in a poster at the 13th International Conference on Malignant Lymphoma taking place in Lugano, Switzerland (abstract #P-274).

Help employers find you! Check out all the jobs and post your resume.